Equibles does not estimate personal net worth.
Get an email with a short summary when SeaStar Medical Holding Corp publishes a filing, an earnings call transcript or a press release.
Get ICU alertsDavid Green is recorded as CFO at SeaStar Medical Holding Corp (ICU) since January 10, 2024, CEO and Chairman at Harvard Apparatus Regenerative Technology, Inc. (HRGN) since November 26, 2021 and Board Member at Harvard Apparatus Regenerative Technology, Inc. (HRGN) since January 1, 2021. The newest filing on record that lists David Green as Board Member at Harvard Apparatus Regenerative Technology, Inc. (HRGN) is dated April 29, 2025. David Green was last confirmed as CFO at Aytu Biopharma, Inc (AYTU) in a filing dated April 7, 2022. SeaStar Medical Holding Corp reported in an 8-K filed August 19, 2025 that David Green was terminated as Chief Financial Officer and Treasurer, effective August 14, 2025. SeaStar Medical Holding Corp reported in an 8-K filed January 11, 2024 that David Green was appointed Chief Financial Officer, effective January 10, 2024. Harvard Apparatus Regenerative Technology, Inc. reported in an 8-K filed January 12, 2023 that David Green was appointed Chief Executive Officer, effective January 11, 2023. The proxy statement of SeaStar Medical Holding Corp reports total compensation of $253,750 for David Green in fiscal 2025, including a base salary of $231,250. Disclosed compensation is on record for 8 fiscal years. David Green has spoken on 4 earnings calls across 2 companies, most recently for SeaStar Medical Holding Corp on May 14, 2025. Those appearances were for SeaStar Medical Holding Corp (ICU) and Aytu Biopharma, Inc (AYTU). SeaStar Medical Holding Corp is classified in the Biotechnology industry within the Healthcare sector. Harvard Apparatus Regenerative Technology, Inc. is classified in the Packaged Foods industry within the Consumer Defensive sector. Other companies whose calls David Green spoke on are classified in the Healthcare sector. Other leadership on record at SeaStar Medical Holding Corp includes Eric Schlorff (CEO, CFO and Board Member), Jennifer A. Baird (Chairman and Board Member), Michael Messinger (CFO) and 4 others.
“On August 13, 2025, the Board of Directors (the "Board") of SeaStar Medical Holding Corporation (the "Company") terminated the employment of David Green, the Company's Chief Financial Officer and Treasurer effective August 14, 2025.”
“On January 10, 2024, the Board of Directors (the "Board") of SeaStar Medical Holding Corporation (the "Company") appointed David Green, age 61, as the Company's Chief Financial Officer, effective as of January 10, 2024.”
“I'll describe our first quarter financial results and conclude with some of our expectations for the remainder of 2025. First, for some housekeeping, please note that our Form 10-Q will be filed with the SEC within the next 24 hours.”
“I'll start with a few comments about our fiscal year ended December 31st, 2024, and conclude with some of our expectations for 2025. First, for some housekeeping, please note that our Form 10-K will be filed with the SEC in the next 24 hours.”
“Today, I'll review the financial results for our third quarter that ended March 31, 2020. As a reminder, we have a June 30 fiscal year end. I'll preface my comments today by sharing that this has been a most productive time for Aytu.”
“I'll do a brief review of our financial results for this first quarter of our 2020 fiscal year that ended September 30, 2019, and then I'll make a few comments on the newly transformed Aytu.”
2024-01-10–present
2021-11-26–present
2021-11-26–present
2021-01-01–present
Last confirmed April 29, 2025
2024-01-10–2025-08-14
Start not stated–2022-04-07
Last confirmed by a filing; no departure on record
Start not stated–2025-08-14
Biotechnology · Healthcare
CFO
2024-01-10–present
Packaged Foods · Consumer Defensive
CEO, Chairman, Board Member
2021-01-01–present
AYTU
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | SeaStar Medical Holding Corp (ICU) | Chief Financial Officer (former) | $231,250 | $253,750 |
| 2024 | SeaStar Medical Holding Corp (ICU) | Chief Financial Officer | $363,702 | $762,152 |
| 2023 | Harvard Apparatus Regenerative Technology, Inc. (HRGN) | Former Chief Executive Officer | $6,566 | $4,567,862 |
| 2022 | Harvard Apparatus Regenerative Technology, Inc. (HRGN) | Former Chief Executive Officer | $35,568 | $37,152 |
| 2021 | Harvard Apparatus Regenerative Technology, Inc. (HRGN) | Chief Executive Officer | $35,568 | $258,539 |
| 2020 | Harvard Apparatus Regenerative Technology, Inc. (HRGN) | Interim Chief Executive Officer | — | — |
| 2019 | Aytu Biopharma, Inc (AYTU) | Former Chief Financial Officer, Secretary and Treasurer, | $250,000 | $685,988 |
| 2018 | Aytu Biopharma, Inc (AYTU) | Chief Financial Officer, Secretary and Treasurer, since December 2017 | $135,000 | $287,000 |
